Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis

dc.creator	Tsivgoulis G., Katsanos A.H., Voumvourakis K., Hadjigeorgiou G.M., Heliopoulos I., Karapanayiotides T., Papathanasopoulos P., Kilidireas C., Grigoriadis N.	en
dc.date.accessioned	2023-01-31T10:16:46Z
dc.date.available	2023-01-31T10:16:46Z
dc.date.issued	2018
dc.identifier	10.1016/j.msard.2018.03.010
dc.identifier.issn	22110348
dc.identifier.uri	http://hdl.handle.net/11615/80067
dc.description.abstract	[No abstract available]	en
dc.language.iso	en	en
dc.source	Multiple Sclerosis and Related Disorders	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046745230&doi=10.1016%2fj.msard.2018.03.010&partnerID=40&md5=17a196c2f9f190eb3315dc6e4cf1d8ea
dc.subject	alemtuzumab	en
dc.subject	beta1a interferon	en
dc.subject	glatiramer	en
dc.subject	natalizumab	en
dc.subject	ocrelizumab	en
dc.subject	glatiramer	en
dc.subject	clinical effectiveness	en
dc.subject	drug efficacy	en
dc.subject	human	en
dc.subject	immunotherapy	en
dc.subject	Letter	en
dc.subject	methodology	en
dc.subject	monotherapy	en
dc.subject	multiple sclerosis	en
dc.subject	randomized controlled trial (topic)	en
dc.subject	therapy effect	en
dc.subject	treatment outcome	en
dc.subject	multiple sclerosis	en
dc.subject	Glatiramer Acetate	en
dc.subject	Humans	en
dc.subject	Multiple Sclerosis	en
dc.subject	Multiple Sclerosis, Relapsing-Remitting	en
dc.subject	Elsevier B.V.	en
dc.title	Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis	en
dc.type	other	en

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.